IL22 and fatty liver disease: Blocking the IAA–AhR–IL-22 axis by treatment with neutralizing anti-IL-22 antibodies abrogates the protective effects of IDO1 deficiency against insulin sensitivity, liver steatosis, and intestinal permeability [148].